TrialBreast (Edinburgh, Scotland)2022

Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression.

Hans Wildiers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.